EN | UA
EN | UA

Help Support

Back

Effect of Boswellia extract formulation in people with moderate COVID-19

COVID-19 COVID-19
COVID-19 COVID-19

A randomized, phase II, double-blind, placebo-controlled clinical trial was carried out to explore the effect of Boswellia extract formulation on the immune system of people with moderate COVID-19.

See All

Key take away

In patients diagnosed with moderate COVID-19, treatment with Boswellia extract formulation led to a decrease in hospital stay, mitigation of SARS-COV-2 clinical symptoms, and reduction in the level of pro-inflammatory cytokines.

Background

A randomized, phase II, double-blind, placebo-controlled clinical trial was carried out to explore the effect of Boswellia extract formulation on the immune system of people with moderate COVID-19.

Method

The study included 47 hospitalized people having moderate COVID-19. Participants were given either Boswellia extract formulation (enriched with boswellic acids, n=24) or placebo (n=23). The clinical symptoms and markers of inflammation were assessed at baseline and trial completion.

Result

In this study, a rise in the percentage of oxygen saturation level was noted in people that received  Boswellia extract formulation in comparison with placebo. The Boswellia extract group exhibited a substantial decrease in the average duration of hospitalization, a rise in the percentage of lymphocytes, and some improvement in clinical symptoms including gustatory dysfunction, headache, myalgia, cough, dyspnea, and olfactory dysfunction.

The hematologic findings indicated a substantial drop in the percentage of neutrophils and neutrophil-to-lymphocyte ratio (NLR) levels in the Boswellia extract group. Furthermore, a considerable drop in C-reactive protein, lactate dehydrogenase, interleukin-6 and tumor necrosis factor-alpha levels was reported in the Boswellia extract group. After the intervention, fewer people in the Boswellia extract group were polymerase chain reaction-positive for COVID-19 in comparison with placebo. However, this was not statistically significant.

Conclusion

Hence, this study supported the benefit of Boswellia extract formulation enriched with boswellic acids as a supportive treatment leading to shorter hospitalization, and mitigation of few clinical symptoms and inflammatory biomarkers linked with coronavirus disease.

Source:

Inflammopharmacology

Article:

Inflawell ® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial

Authors:

Sepideh Barzin Tond et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: